Prosthesis structure

Abstract

The present invention provides a prosthetic structure, comprising: a base portion; a porous portion disposed on one side of the base portion; a drug-carrying portion disposed within the base portion and / or the porous portion, the drug-carrying portion comprising: a drug delivery channel having an inlet end and an outlet end; an inner drug-carrying chamber communicating with the drug delivery channel, the inner drug-carrying chamber comprising an inner main cavity disposed at the inlet end and an inner extension cavity communicatively disposed on the cavity wall of the inner main cavity and extending away from the drug delivery channel; and an outer drug-carrying chamber communicating with the inner drug-carrying chamber, the outer drug-carrying chamber comprising an outer main cavity surrounding the outer side of the inner drug-carrying chamber and an outer extension cavity communicatively disposed on the cavity wall of the outer main cavity and extending away from the drug delivery channel. The technical solution of the present application effectively solves the problem in the related art of being unable to provide drugs for a long period of time at the location where the body's autologous bone contacts the prosthetic structure.

Description

Technical Field

[0001] The present invention relates to the field of medical devices, and in particular to a prosthetic structure. Background Art

[0002] In the prior art, after a prosthetic structure is implanted in the human body, infection is prone to occur at the point where the body's autologous bone contacts the prosthetic structure. Therefore, medication must be administered to the contact area for a long period of time to prevent infection. In the prior art, long-term oral antibiotics are commonly used to prevent infection. However, oral antibiotics are difficult to fully penetrate the designated contact points between the body's autologous bone and the prosthetic structure, and oral antibiotics can cause side effects such as liver and kidney damage.

[0003] The related technology is unable to provide drugs for a long time at the location where the body's autologous bone contacts the prosthetic structure. Summary of the Invention

[0004] The main purpose of the present invention is to provide a prosthetic structure to solve the problem in the related art that drugs cannot be provided for a long time at the position where the body's autologous bone contacts the prosthetic structure.

[0005] In order to achieve the above-mentioned objectives, the present invention provides a prosthesis structure, comprising: a base portion; a porous portion, arranged on one side of the base portion; a drug-carrying portion, arranged in the base portion and / or the porous portion, the drug-carrying portion comprising: a drug output channel, the drug output channel having an inlet end and an outlet end; an inner drug-carrying chamber, connected to the drug output channel, the inner drug-carrying chamber comprising an inner main cavity arranged at the inlet end and an inner expansion cavity communicatively arranged on the cavity wall of the inner main cavity and extending in a direction away from the drug output channel; an outer drug-carrying chamber, connected to the inner drug-carrying chamber, the outer drug-carrying chamber comprising an outer main cavity surrounding the outer side of the inner drug-carrying chamber and an outer expansion cavity communicatively arranged on the cavity wall of the outer main cavity and extending in a direction away from the drug output channel, wherein the inner expansion cavity is provided with a first drug-passing channel communicating with the inner main cavity and the outer main cavity.

[0006] Furthermore, the prosthesis structure further includes: an intermediate drug loading chamber, which is disposed between the inner drug loading chamber and the outer drug loading chamber and communicates with the inner drug loading chamber and the outer drug loading chamber.

[0007] Furthermore, the inner layer expansion cavity includes a first inner layer expansion cavity and a plurality of second inner layer expansion cavities arranged at intervals. The volume of the first inner layer expansion cavity is smaller than the volume of the inner main cavity. The volume of each second inner layer expansion cavity is smaller than the volume of the first inner layer expansion cavity. The plurality of second inner layer expansion cavities are arranged on the cavity wall of the first inner layer expansion cavity and extend in a direction away from the drug output channel. The first inner layer expansion cavity is connected to the plurality of second inner layer expansion cavities, and the first drug passage is arranged on the cavity wall of the second inner layer expansion cavity.

[0008] Furthermore, the outer layer expansion cavity includes a first outer layer expansion cavity and a plurality of second outer layer expansion cavities arranged at intervals. The volume of the first outer layer expansion cavity is smaller than the volume of the outer layer main cavity. The volume of each second outer layer expansion cavity is smaller than the volume of the first outer layer expansion cavity. The plurality of second outer layer expansion cavities are arranged on the cavity wall of the first outer layer expansion cavity and extend in a direction away from the drug output channel. The first outer layer expansion cavity is connected to the plurality of second outer layer expansion cavities.

[0009] Furthermore, the inner main cavity, the first inner expansion cavity, the second inner expansion cavity, the outer main cavity, the first outer expansion cavity and the second outer expansion cavity are all spherical structures.

[0010] Furthermore, the inner main cavity is connected to the inner expansion cavity through a first connecting port, and the flow area of ​​the first connecting port is smaller than the maximum cross-sectional area of ​​the inner expansion cavity; the outer main cavity is connected to the outer expansion cavity through a second connecting port, and the flow area of ​​the second connecting port is smaller than the maximum cross-sectional area of ​​the outer expansion cavity.

[0011] Furthermore, there are multiple intermediate drug loading chambers, and the multiple intermediate drug loading chambers are nested and arranged between the inner drug loading chamber and the outer drug loading chamber, and the multiple intermediate drug loading chambers are interconnected.

[0012] Furthermore, the middle layer drug loading chamber includes a middle layer main cavity arranged around the outside of the middle layer drug loading chamber and a middle layer expansion cavity arranged on the cavity wall of the middle layer main cavity and extending in a direction away from the drug output channel, wherein a second drug passing channel is provided on the middle layer expansion cavity, the second drug passing channel connecting the outer layer drug loading chamber and the middle layer drug loading chamber, and the first drug passing channel connecting the middle layer drug loading chamber and the inner layer drug loading chamber.

[0013] Furthermore, the drug output channel extends in a direction from the porous portion to the base portion, and the inner drug loading chamber and the outer drug loading chamber are protrudingly arranged in the direction from the porous portion to the base portion.

[0014] Furthermore, there are multiple drug-carrying parts, and the multiple drug-carrying parts are arranged at intervals in the porous part; there are multiple inner layer expansion cavities, and the multiple inner layer expansion cavities are arranged at intervals on the cavity wall of the inner layer main cavity; there are multiple outer layer expansion cavities, and the multiple outer layer expansion cavities are arranged at intervals on the cavity wall of the outer layer main cavity; the minimum distance between the outer layer main cavity and the side of the porous part away from the base part is in the range of 1mm to 2mm.

[0015] Applying the technical solution of the present invention, the prosthetic structure includes: a base part, a porous part and a drug-carrying part. The porous part is arranged on one side of the base part. After the prosthetic structure is implanted into the human body, the porous part contacts the human body's autologous bone to facilitate the growth of the human body's autologous bone into the porous part, thereby increasing the stability of the prosthetic structure after implantation into the human body. The drug-carrying part is arranged in the base part and / or the porous part, and the drug-carrying part includes: a drug output channel, an inner drug-carrying chamber and an outer drug-carrying chamber. The drug output channel has an inlet end and an outlet end. The inner drug-carrying chamber and the outer drug-carrying chamber are connected by a first drug-passing channel. Therefore, the inner drug-carrying chamber and the outer drug-carrying chamber are both connected to the drug output channel, which facilitates the delivery of the drugs in the inner drug-carrying chamber and the outer drug-carrying chamber through the drug output channel to the position where the human body's autologous bone contacts the prosthetic structure. The inner drug loading chamber includes an inner main cavity disposed at the inlet end and an inner expansion cavity that is communicatively disposed on the cavity wall of the inner main cavity and extends in a direction away from the drug output channel. The provision of the inner expansion cavity expands the volume of the inner drug loading chamber, allowing the inner drug loading chamber to accommodate more drugs. The outer drug loading chamber is communicated with the inner drug loading chamber and includes an outer main cavity disposed around the outer side of the inner drug loading chamber and an outer expansion cavity that is communicatively disposed on the cavity wall of the outer main cavity and extends in a direction away from the drug output channel. The provision of the outer expansion cavity expands the volume of the outer drug loading chamber, allowing the outer drug loading chamber to accommodate more drugs. To facilitate communication between the inner and outer drug loading chambers, a first drug passage connecting the inner and outer main cavities is provided on the inner expansion cavity. The drug in the outer drug loading chamber needs to pass through the first drug passage, the inner drug loading chamber, and the drug output passage in sequence to be delivered to the point where the body's autologous bone contacts the prosthetic structure. This increases the time it takes for the drug in the outer drug loading chamber to reach the point where the body's autologous bone contacts the prosthetic structure, prolonging the time the prosthetic structure provides the drug to the point where the body's autologous bone contacts the prosthetic structure, thereby achieving the purpose of sustained drug release. Therefore, the technical solution of this application effectively solves the problem in related technologies of being unable to provide the drug to the point where the body's autologous bone contacts the prosthetic structure for a long period of time. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] The accompanying drawings, which constitute part of this application, are intended to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are intended to explain the present invention and do not constitute an undue limitation of the present invention. In the accompanying drawings:

[0017] Figure 1 A schematic cross-sectional view showing an embodiment of a prosthetic structure according to the present invention;

[0018] Figure 2 Shown Figure 1 A partial enlarged view of the prosthetic structure at point A;

[0019] Figure 3 Shown Figure 2 A partial enlarged view of point B of the prosthetic structure.

[0020] The above drawings include the following reference numerals:

[0021] 10. Base part;

[0022] 20. Porous part;

[0023] 30. Medicine-carrying department;

[0024] 31, inner drug loading chamber; 311, inner main cavity; 312, inner expansion cavity; 3121, first inner expansion cavity; 3122, second inner expansion cavity; 313, first drug passage; 314, first communication port;

[0025] 32, middle layer drug loading chamber; 321, middle layer main cavity; 322, middle layer expansion cavity; 3221, first middle layer expansion cavity; 3222, second middle layer expansion cavity; 323, second drug passage; 324, second communication port;

[0026] 33, outer drug loading chamber; 331, outer main cavity; 332, outer expansion cavity; 3321, first outer expansion cavity; 3322, second outer expansion cavity;

[0027] 34. Drug output channel; 341. Inlet end; 342. Outlet end;

[0028] 40. Human autologous bone. DETAILED DESCRIPTION

[0029] The following will be combined with the accompanying drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the embodiments described are only part of the embodiments of the present invention, rather than all the embodiments. The following description of at least one exemplary embodiment is actually only illustrative and is in no way intended to limit the present invention and its application or use. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.

[0030] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprise" and / or "include" are used in this specification, they indicate the presence of features, steps, operations, devices, components and / or combinations thereof.

[0031] Unless otherwise specifically stated, the relative arrangement of the parts and steps, the numerical expressions and the numerical values ​​set forth in these embodiments do not limit the scope of the present invention. At the same time, it should be understood that, for ease of description, the sizes of the various parts shown in the drawings are not drawn according to the actual proportional relationship. The techniques, methods and equipment known to those of ordinary skill in the relevant art may not be discussed in detail, but where appropriate, the techniques, methods and equipment should be considered as part of the authorization specification. In all examples shown and discussed here, any specific values ​​should be interpreted as being merely exemplary and not as limiting. Therefore, other examples of the exemplary embodiments may have different values. It should be noted that similar numbers and letters represent similar items in the following figures, and therefore, once an item is defined in one figure, it does not need to be further discussed in subsequent figures.

[0032] like Figure 1 and Figure 2 As shown, the prosthetic structure of this embodiment includes: a base portion 10, a porous portion 20 and a drug loading portion 30. The porous portion 20 is arranged on one side of the base portion 10. The drug loading portion 30 is arranged in the porous portion 20, and the drug loading portion 30 includes: a drug output channel 34, an inner drug loading chamber 31 and an outer drug loading chamber 33. The drug output channel 34 has an inlet end 341 and an outlet end 342. The inner drug loading chamber 31 is connected to the drug output channel 34, and the inner drug loading chamber 31 includes an inner main cavity 311 arranged at the inlet end 341 and an inner extension cavity 312 that is arranged on the cavity wall of the inner main cavity 311 and extends in a direction away from the drug output channel 34. The outer drug loading chamber 33 is connected to the inner drug loading chamber 31 and includes an outer main cavity 331 surrounding the outer side of the inner drug loading chamber 31 and an outer extension cavity 332 disposed on the wall of the outer main cavity 331 and extending away from the drug delivery channel 34. The inner extension cavity 312 is provided with a first drug passage 313 connecting the inner main cavity 311 and the outer main cavity 331.

[0033] Using the technical solution of this embodiment, the prosthetic structure includes: a base portion 10, a porous portion 20, and a drug-carrying portion 30. The porous portion 20 is disposed on one side of the base portion 10. After the prosthetic structure is implanted in the human body, the porous portion 20 contacts the body's autologous bone, facilitating the in-growth of the body's autologous bone into the porous portion 20 and increasing the stability of the prosthetic structure after implantation. The drug-carrying portion 30 is disposed within the porous portion 20 and includes: a drug delivery channel 34, an inner drug loading chamber 31, and an outer drug loading chamber 33. The drug delivery channel 34 has an inlet end 341 and an outlet end 342. The inner drug loading chamber 31 and the outer drug loading chamber 33 are connected by a first drug delivery channel 313. Therefore, both the inner drug loading chamber 31 and the outer drug loading chamber 33 are connected to the drug delivery channel 34, facilitating the delivery of drugs within the inner drug loading chamber 31 and the outer drug loading chamber 33 through the drug delivery channel 34 to the point where the drug contacts the body's autologous bone. The inner drug loading chamber 31 includes an inner main chamber 311 at the inlet end 341 and an inner expansion chamber 312, which is interconnected and arranged on the wall of the inner main chamber 311 and extends away from the drug delivery channel 34. The inner expansion chamber 312 increases the volume of the inner drug loading chamber 31, allowing it to accommodate more drug. The outer drug loading chamber 33 is interconnected with the inner drug loading chamber 31 and includes an outer main chamber 331 surrounding the outer side of the inner drug loading chamber 31 and an outer expansion chamber 332, which is interconnected and arranged on the wall of the outer main chamber 331 and extends away from the drug delivery channel 34. The outer expansion chamber 332 increases the volume of the outer drug loading chamber 33, allowing it to accommodate more drug. To facilitate the connection between the inner drug loading chamber 31 and the outer drug loading chamber 33, a first drug passage 313 is provided on the inner expansion chamber 312, connecting the inner main chamber 311 and the outer main chamber 331. The drug in the outer drug loading chamber 33 needs to pass through the first drug passage 313, the inner drug loading chamber 31, and the drug output channel 34 in sequence to be delivered to the point where the body's autologous bone contacts the prosthetic structure. This increases the time it takes for the drug in the outer drug loading chamber 33 to reach the point where the body's autologous bone contacts the prosthetic structure, prolonging the time it takes for the prosthetic structure to provide the drug to the point where the body's autologous bone contacts the prosthetic structure, thereby achieving the purpose of sustained drug release. Therefore, the technical solution of this embodiment effectively solves the problem in the related art of being unable to provide the drug to the point where the body's autologous bone contacts the prosthetic structure for a long time.

[0034] It should be noted that the inlet end 341 is the end of the drug delivery channel 34 connected to the wall of the inner main cavity 311, and the outlet end 342 is the end of the drug delivery channel 34 facing away from the base portion 10. After the prosthetic structure is implanted in the human body, the outlet end 342 communicates with the body's autologous bone. The drug in the drug-carrying portion 30 is transported through the drug delivery channel 34 to the point where the body's autologous bone contacts the prosthetic structure. At this point, the drug in the drug delivery channel 34 is transported from the inlet end 341 to the outlet end 342.

[0035] Furthermore, the prosthetic structure is suitable for prosthetic structures that are in contact with bones and require sustained drug release. The prosthetic structure of this embodiment has the function of sustained drug release, can continuously exert the efficacy of the drug, and prolong the time of drug release. According to the corresponding design of the required amount of drug and the volume of the drug-loading cavity, the purpose of drug treatment can be achieved within a specified period. And the prosthetic structure of this embodiment can achieve the function of replacing autologous bone, treating lesions, and promoting body growth. The prosthetic structure can be a joint prosthesis or a bone defect patch, for example: a hip joint prosthesis, a knee joint prosthesis, a hip bone defect patch, and a knee bone defect patch.

[0036] In this embodiment, the prosthetic structure's base portion 10, porous portion 20, and drug-carrying portion 30 are integrated and formed using electron beam melting (EBM) metal 3D printing technology. Electron beam melting (EBM) metal 3D printing falls under the additive manufacturing category and can process complex and irregular structures.

[0037] In an embodiment not shown in the drawings, the drug carrying portion is disposed in the base portion, or a portion of the drug carrying portion is disposed in the base portion and the other portion is disposed in the porous portion.

[0038] like Figure 1 and Figure 2 As shown, the prosthetic structure further includes an intermediate drug loading chamber 32, which is disposed between the inner drug loading chamber 31 and the outer drug loading chamber 33 and connects the inner drug loading chamber 31 and the outer drug loading chamber 33. The drug in the outer drug loading chamber 33 needs to pass through the intermediate drug loading chamber 32 before reaching the inner drug loading chamber 31, and then be output from the drug output channel 34 connected to the inner drug loading chamber 31 to the point where the body's autologous bone contacts the prosthetic structure, further increasing the time it takes for the drug in the outer drug loading chamber 33 to reach the point where the body's autologous bone contacts the prosthetic structure.

[0039] like Figure 1 and Figure 2As shown, the inner expansion cavity 312 includes a first inner expansion cavity 3121 and a plurality of spaced-apart second inner expansion cavities 3122. The provision of the plurality of second inner expansion cavities 3122 further expands the volume of the inner expansion cavity 312, allowing the inner expansion cavity 312 to accommodate more medication. The volume of the first inner expansion cavity 3121 is smaller than that of the inner main cavity 311, and the volume of each second inner expansion cavity 3122 is smaller than that of the first inner expansion cavity 3121. The plurality of second inner expansion cavities 3122 are disposed on the wall of the first inner expansion cavity 3121 and extend away from the medication delivery channel 34. The first inner expansion cavity 3121 is connected to the plurality of second inner expansion cavities 3122, and the first medication delivery channel 313 is disposed on the wall of the second inner expansion cavity 3122. In this way, the medicine in the middle layer drug loading chamber 32 needs to pass through the first drug passage 313, the second inner layer expansion chamber 3122 and the first inner layer expansion chamber 3121 in sequence to enter the inner layer main chamber 311, and since the volumes of the inner layer main chamber 311, the first inner layer expansion chamber 3121 and the second inner layer expansion chamber 3122 are reduced in sequence, the time for the medicine in the middle layer drug loading chamber 32 to enter the inner layer main chamber 311 can be further extended.

[0040] like Figure 1 and Figure 2 As shown, the outer expansion chamber 332 includes a first outer expansion chamber 3321 and a plurality of spaced-apart second outer expansion chambers 3322. The provision of the plurality of second outer expansion chambers 3322 further expands the volume of the outer expansion chamber 332, allowing it to accommodate more medication. The volume of the first outer expansion chamber 3321 is smaller than that of the outer main chamber 331, and the volume of each second outer expansion chamber 3322 is smaller than that of the first outer expansion chamber 3321. The plurality of second outer expansion chambers 3322 are disposed on the wall of the first outer expansion chamber 3321 and extend away from the medication delivery channel 34. The first outer expansion chamber 3321 is in communication with the plurality of second outer expansion chambers 3322. In this way, the medicine in the second outer expansion cavity 3322 needs to enter the outer main cavity 331 through the second outer expansion cavity 3322, and since the volumes of the outer main cavity 331, the first outer expansion cavity 3321, and the second outer expansion cavity 3322 decrease in sequence, the time for the medicine in the second outer expansion cavity 3322 to enter the outer main cavity 331 can be further extended.

[0041] like Figure 1 and Figure 2 As shown, the inner main cavity 311, the first inner expansion cavity 3121, the second inner expansion cavity 3122, the outer main cavity 331, the first outer expansion cavity 3321, and the second outer expansion cavity 3322 are all spherical structures. The spherical structure is larger and can accommodate more drugs. Furthermore, the spherical structure simulates the structure of human alveoli, further increasing drug loading.

[0042] In an embodiment not shown in the figure, the inner main cavity, the first inner expansion cavity, the second inner expansion cavity, the outer main cavity, the first outer expansion cavity and the second outer expansion cavity can be triangular pyramids, triangular prisms or cubes.

[0043] like Figures 1 to 3 As shown, the inner main cavity 311 communicates with the inner expansion cavity 312 via a first communication port 314. The flow area of ​​the first communication port 314 is smaller than the maximum cross-sectional area of ​​the inner expansion cavity 312. That is, the inner main cavity 311 forms a major arc (an arc larger than a semicircle) in a cross-sectional view passing through the center of the spherical structure of the inner main cavity 311. This prevents some of the drug in the inner expansion cavity 312 from being directly discharged from the first communication port 314 into the inner main cavity 311, thereby extending the time it takes for the drug in the inner expansion cavity 312 to be delivered to the inner main cavity 311.

[0044] like Figures 1 to 3 As shown, the outer main cavity 331 communicates with the outer expansion cavity 332 via the second communication port 324. The flow area of ​​the second communication port 324 is smaller than the maximum cross-section of the outer expansion cavity 332. That is, the outer main cavity 331 forms a major arc (an arc larger than a semicircle) in a cross-sectional view passing through the center of the spherical structure of the outer main cavity 331. This prevents some of the drug in the outer expansion cavity 332 from being directly discharged from the second communication port 324 into the outer main cavity 331, thereby extending the time it takes for the drug in the outer expansion cavity 332 to be delivered to the outer main cavity 331.

[0045] Specifically, the inner main cavity 311, the first inner expansion cavity 3121, the second inner expansion cavity 3122, the outer main cavity 331, the first outer expansion cavity 3321, and the second outer expansion cavity 3322 all have spherical segment structures. The first communication port 314 is the bottom surface of the spherical segment structure of the first inner expansion cavity 3121, and the second communication port 324 is the bottom surface of the spherical segment structure of the first outer expansion cavity 3321.

[0046] like Figures 1 to 3 As shown, in this embodiment, there is one drug-carrying cavity in the middle layer.

[0047] In an embodiment not shown in the figures, multiple intermediate drug loading chambers are provided, nested between the inner and outer drug loading chambers, and interconnected. Thus, the drug in the outer drug loading cavity must pass through the multiple intermediate drug loading chambers before reaching the inner drug loading cavity, further increasing the time it takes for the drug in the outer drug loading cavity to reach the inner drug loading cavity. This allows the drug to be delivered to the contact point between the body's autologous bone and the prosthetic structure over a long period of time through the drug delivery channel connected to the inner drug loading cavity.

[0048] like Figures 1 to 3As shown, the intermediate drug loading chamber 32 includes an intermediate main cavity 321 disposed around the outer side of the intermediate drug loading chamber 32, and an intermediate expansion cavity 322 disposed on the wall of the intermediate main cavity 321 and extending away from the drug delivery channel 34. The provision of the intermediate expansion cavity 322 expands the volume of the intermediate drug loading chamber 32, allowing it to accommodate more drugs. A second drug passage 323 is provided in the intermediate expansion cavity 322, connecting the outer drug loading chamber 33 and the intermediate drug loading chamber 32. The first drug passage 313 connects the intermediate drug loading chamber 32 and the inner drug loading chamber 31. The provision of the first and second drug passages 313 allows drugs in the outer drug loading chamber 33 to be delivered to both the intermediate and inner drug loading chambers 32 and 31.

[0049] In this embodiment, the intermediate layer expansion cavity 322 includes a first intermediate layer expansion cavity 3221 and a plurality of spaced-apart second intermediate layer expansion cavities 3222. The volume of the first intermediate layer expansion cavity 3221 is smaller than that of the intermediate layer main cavity 321, and the volume of each second intermediate layer expansion cavity 3222 is smaller than that of the first intermediate layer expansion cavity 3221. The plurality of second intermediate layer expansion cavities 3222 are disposed on the wall of the first intermediate layer expansion cavity 3221 and extend away from the drug delivery channel 34. The first intermediate layer expansion cavity 3221 is connected to the plurality of second intermediate layer expansion cavities 3222. The second drug passage 323 is disposed on the wall of the second intermediate layer expansion cavity 3222. Furthermore, the first drug passage 313 is disposed on the wall of the second inner layer expansion cavity 3122, and the flow area of ​​the first drug passage 313 is smaller than the maximum cross-sectional area of ​​the second inner layer expansion cavity 3122. In this way, as the human body moves, the drug can slowly enter the second inner layer expansion cavity 3122 from the middle layer main cavity 321, thereby extending the drug delivery time and further achieving the effect of sustained drug release.

[0050] Furthermore, the second drug passage 323 is disposed on the wall of the second intermediate layer expansion cavity 3222. The flow area of ​​the second drug passage 323 is smaller than the maximum cross-sectional area of ​​the second intermediate layer expansion cavity 3222. This allows the drug to slowly flow from the outer layer main cavity into the second intermediate layer expansion cavity 3222 as the body moves, extending the drug delivery time and further achieving a sustained drug release effect.

[0051] like Figures 1 to 3 As shown, the drug output channel 34 extends in the direction from the porous portion 20 to the base portion 10, and the inner drug loading chamber 31 and the outer drug loading chamber 33 are protruded in the direction from the porous portion 20 to the base portion 10, so as to facilitate the connection between the drug output channel 34 and the inner drug loading chamber 31, and also facilitate the output of the drug in the drug loading chamber to the position of the human body's autologous bone in contact with the porous portion 20.

[0052] In this embodiment, the drug output channel 34 extends vertically from the porous portion 20 to the base portion 10 , and the inner drug loading chamber 31 and the outer drug loading chamber 33 are vertically protruded in the direction from the porous portion 20 to the base portion 10 .

[0053] In an embodiment not shown in the figures, according to the shape requirements of the prosthetic structure and the mechanical performance requirements of the prosthetic structure, the drug output channel extends non-vertically from the porous portion to the base portion, and the inner drug loading chamber and the outer drug loading chamber are arranged to protrude non-vertically from the porous portion to the base portion.

[0054] like Figures 1 to 3 As shown, there are multiple drug loading sections 30, each of which is spaced apart within the porous section 20. There are multiple inner expansion cavities 312, each of which is spaced apart on the wall of the inner main cavity 311. The provision of multiple inner expansion cavities 312 expands the volume of the inner drug loading cavity, further enabling the inner drug loading chamber 31 to accommodate more drug. There are multiple outer expansion cavities 332, each of which is spaced apart on the wall of the outer main cavity 331. The provision of multiple outer expansion cavities 332 expands the volume of the outer drug loading cavity, further enabling the outer drug loading chamber 33 to accommodate more drug.

[0055] like Figures 1 to 3 As shown, since the depth required for the body's autologous bone to grow into the porous portion 20 is less than 1 mm, the minimum distance between the outer main cavity 331 and the side of the porous portion 20 away from the base portion 10 is within a range of 1 mm to 2 mm. This increases the contact area between the body's autologous bone and the porous structure, facilitates the body's autologous bone growth into the porous portion 20, and increases the stability of the prosthetic structure after implantation. In this embodiment, the minimum distance between the outer main cavity 331 and the side of the porous portion 20 away from the base portion 10 is preferably 1 mm, 1.2 mm, 1.5 mm, 1.8 mm, or 2 mm.

[0056] In this embodiment, there are multiple middle layer expansion cavities 322 , and the multiple middle layer expansion cavities 322 are arranged at intervals on the cavity wall of the middle layer main cavity 321 .

[0057] Furthermore, the thickness of the porous portion 20 is in the range of 5 mm to 15 mm, and the drug loading capacity of each drug loading portion 30 is in the range of 1 ml to 5 ml. The drug is loaded into the drug loading portion 30 by soaking, injection or squeezing. When the drug is loaded into the drug loading portion 30, the drug passes through the outlet end 342 of the drug output channel 34, the inlet end 341 of the drug output channel 34, the inner main cavity 311, the inner expansion cavity 312, the middle main cavity 321, the middle expansion cavity 322, the outer main cavity 331 and the outer expansion cavity 332 in sequence to fill the drug loading portion 30. The prosthetic structure in this embodiment can be loaded with multiple drugs by injecting or squeezing different drugs into different drug loading cavities to achieve better therapeutic effects. In this embodiment, the thickness of the porous portion 20 is preferably 5 mm, 8 mm, 10 mm, 12 mm or 15 mm.

[0058] In this embodiment, a drug-carrying portion 30 has a single inner main cavity 311. A spherical inner main cavity 311 has an inner expansion cavity 312 disposed at the vertex of its spherical surface. Surrounding the inner expansion cavity 312 at the vertex of the spherical surface are six inner expansion cavities 312 disposed on the spherical cross-section of the inner main cavity 311. Twelve inner expansion cavities 312 are disposed on the spherical cross-section of the inner main cavity 311 of the spherical structure facing away from the base portion 10. In an embodiment not shown in the figures, the number of inner expansion cavities can be increased to facilitate an increase in drug loading capacity, based on clinical application requirements and while ensuring satisfactory mechanical properties.

[0059] In this embodiment, a drug loading portion 30 has a single intermediate layer main cavity 321. A spherical intermediate layer main cavity 321 has a single intermediate layer expansion cavity 322 disposed at the apex of the spherical surface. Surrounding the intermediate layer expansion cavity 322 at the apex of the spherical surface are six intermediate layer expansion cavities 322 disposed on the spherical cross-section of the spherical intermediate layer main cavity 321. A spherical intermediate layer main cavity 321 has twelve intermediate layer expansion cavities 322 disposed on the spherical cross-section facing away from the base portion 10. In an embodiment not shown in the figures, the number of intermediate layer expansion cavities can be increased to facilitate increased drug loading, based on clinical application requirements and while ensuring satisfactory mechanical properties.

[0060] In this embodiment, a drug loading portion 30 has a single outer main cavity 331. A spherical outer main cavity 331 has an outer expansion cavity 332 disposed at the apex of its spherical surface. Surrounding the outer expansion cavity 332 at the apex of the spherical surface are six outer expansion cavities 332 disposed on the spherical cross-section of the outer main cavity 331. A spherical outer main cavity 331 has twelve outer expansion cavities 332 disposed on the spherical cross-section facing away from the base portion 10. In an embodiment not shown in the figures, the number of outer expansion cavities can be increased to facilitate increased drug loading, based on clinical application requirements and while ensuring satisfactory mechanical properties.

[0061] In an embodiment not shown in the figure, the inner drug-loading cavity, the middle drug-loading cavity and the outer drug-loading cavity are arranged in the base part, the inner main cavity of the inner drug-loading cavity is connected to the inlet end of the drug output channel, and the outlet end of the drug output channel is passed through the porous part and is connected to the outside of the prosthetic structure.

[0062] In an embodiment not shown in the figure, a part of the inner drug-loading cavity, a part of the middle drug-loading cavity and a part of the outer drug-loading cavity are arranged in the base part, another part of the inner drug-loading cavity, another part of the middle drug-loading cavity and another part of the outer drug-loading cavity are arranged in the porous part, the inner main cavity 311 of the inner drug-loading cavity is connected to the inlet end of the drug output channel, and the outlet end of the drug output channel is connected to the outside of the prosthetic structure.

[0063] In the description of the present invention, it should be understood that the directions or positional relationships indicated by directional words such as "front, back, up, down, left, right", "horizontal, vertical, perpendicular, horizontal" and "top, bottom" are usually based on the directions or positional relationships shown in the accompanying drawings. They are only for the convenience of describing the present invention and simplifying the description. Unless otherwise specified, these directional words do not indicate or imply that the device or element referred to must have a specific direction or be constructed and operated in a specific direction. Therefore, they cannot be understood as limiting the scope of protection of the present invention; the directional words "inside and outside" refer to the inside and outside relative to the outline of each component itself.

[0064] For ease of description, spatially relative terms such as "above", "above", "on the upper surface of", "above", etc. may be used herein to describe the spatial positional relationship of a device or feature to other devices or features as shown in the figures. It should be understood that spatially relative terms are intended to include different orientations of the device in use or operation in addition to the orientation described in the figures. For example, if the device in the drawings is inverted, the device described as "above other devices or structures" or "above other devices or structures" will be positioned as "below other devices or structures" or "below other devices or structures". Thus, the exemplary term "above" can include both "above" and "below". The device can also be positioned in other different ways (rotated 90 degrees or in other orientations), and the spatially relative descriptions used here are interpreted accordingly.

[0065] In addition, it should be noted that the use of terms such as "first" and "second" to limit components is only for the convenience of distinguishing the corresponding components. Unless otherwise stated, the above terms have no special meaning and therefore cannot be understood as limiting the scope of protection of the present invention.

[0066] The foregoing description is merely a preferred embodiment of the present invention and is not intended to limit the present invention. Those skilled in the art will readily appreciate that various modifications and variations of the present invention are possible. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the present invention are intended to be within the scope of protection of the present invention.

Claims

1. A prosthetic structure, characterized in that: include: Basal part (10); A porous portion (20) is provided on one side of the base portion (10); The drug-carrying portion (30) is arranged in the base portion (10) and / or the porous portion (20), and the drug-carrying portion (30) comprises: a drug output channel (34), the drug output channel (34) having an inlet end (341) and an outlet end (342), wherein the drug in the drug-carrying portion (30) is transported through the drug output channel (34) to a position where the body's autologous bone contacts the prosthetic structure; an inner drug loading chamber (31) connected to the drug output channel (34), the inner drug loading chamber (31) comprising an inner main chamber (311) disposed at the inlet end (341) and an inner expansion chamber (312) disposed on a wall of the inner main chamber (311) and extending in a direction away from the drug output channel (34); The outer drug loading chamber (33) is connected to the inner drug loading chamber (31), and the outer drug loading chamber (33) includes an outer main cavity (331) arranged around the outer side of the inner drug loading chamber (31) and an outer extension cavity (332) arranged on the cavity wall of the outer main cavity (331) and extending in a direction away from the drug output channel (34), wherein the inner extension cavity (312) is provided with a first drug passage (313) connecting the inner main cavity (311) and the outer main cavity (331).

2. The prosthetic structure according to claim 1, characterized in that The prosthetic structure further comprises: The middle layer drug loading chamber (32) is arranged between the inner layer drug loading chamber (31) and the outer layer drug loading chamber (33), and is in communication with the inner layer drug loading chamber (31) and the outer layer drug loading chamber (33).

3. The prosthetic structure according to claim 1, characterized in that The inner layer expansion cavity (312) includes a first inner layer expansion cavity (3121) and a plurality of second inner layer expansion cavities (3122) arranged at intervals. The volume of the first inner layer expansion cavity (3121) is smaller than the volume of the inner layer main cavity (311). The volume of each second inner layer expansion cavity (3122) is smaller than the volume of the first inner layer expansion cavity (3121). The plurality of second inner layer expansion cavities (3122) are arranged on the cavity wall of the first inner layer expansion cavity (3121) and extend in a direction away from the drug output channel (34). The first inner layer expansion cavity (3121) is connected to the plurality of second inner layer expansion cavities (3122). The first drug passage (313) is arranged on the cavity wall of the second inner layer expansion cavity (3122).

4. The prosthetic structure according to claim 3, characterized in that The outer layer expansion cavity (332) includes a first outer layer expansion cavity (3321) and a plurality of second outer layer expansion cavities (3322) arranged at intervals. The volume of the first outer layer expansion cavity (3321) is smaller than the volume of the outer layer main cavity (331). The volume of each second outer layer expansion cavity (3322) is smaller than the volume of the first outer layer expansion cavity (3321). The plurality of second outer layer expansion cavities (3322) are arranged on the cavity wall of the first outer layer expansion cavity (3321) and extend in a direction away from the drug output channel (34). The first outer layer expansion cavity (3321) is connected to the plurality of second outer layer expansion cavities (3322).

5. The prosthetic structure according to claim 4, characterized in that The inner layer main cavity (311), the first inner layer expansion cavity (3121), the second inner layer expansion cavity (3122), the outer layer main cavity (331), the first outer layer expansion cavity (3321) and the second outer layer expansion cavity (3322) are all spherical segment structures.

6. The prosthetic structure according to claim 5, characterized in that The inner main cavity (311) is in communication with the inner expansion cavity (312) via a first communication port (314), and the flow area of ​​the first communication port (314) is smaller than the maximum cross-sectional area of ​​the inner expansion cavity (312); The outer main cavity (331) is in communication with the outer expansion cavity (332) via a second communication port (324), and the flow area of ​​the second communication port (324) is smaller than the maximum cross-sectional area of ​​the outer expansion cavity (332).

7. The prosthetic structure according to claim 2, characterized in that There are a plurality of intermediate drug loading chambers (32), and the plurality of intermediate drug loading chambers (32) are nested and arranged between the inner drug loading chamber (31) and the outer drug loading chamber (33), and the plurality of intermediate drug loading chambers (32) are interconnected.

8. The prosthetic structure according to claim 2, characterized in that The intermediate layer drug loading chamber (32) includes an intermediate layer main cavity (321) arranged around the outer side of the intermediate layer drug loading chamber (32) and an intermediate layer extension cavity (322) arranged on the cavity wall of the intermediate layer main cavity (321) and extending in a direction away from the drug output channel (34), wherein a second drug passage (323) is provided on the intermediate layer extension cavity (322), the second drug passage (323) connecting the outer layer drug loading chamber (33) and the intermediate layer drug loading chamber (32), and the first drug passage (313) connecting the intermediate layer drug loading chamber (32) and the inner layer drug loading chamber (31).

9. The prosthetic structure according to claim 1, characterized in that The drug output channel (34) extends in the direction from the porous portion (20) to the base portion (10), and the inner drug loading chamber (31) and the outer drug loading chamber (33) are protrudingly arranged in the direction from the porous portion (20) to the base portion (10).

10. The prosthetic structure according to claim 1, characterized in that There are multiple drug-carrying parts (30), and the multiple drug-carrying parts (30) are arranged at intervals in the porous part (20); there are multiple inner layer expansion cavities (312), and the multiple inner layer expansion cavities (312) are arranged at intervals on the cavity wall of the inner layer main cavity (311); there are multiple outer layer expansion cavities (332), and the multiple outer layer expansion cavities (332) are arranged at intervals on the cavity wall of the outer layer main cavity (331); the minimum distance between the outer layer main cavity (331) and the side of the porous part (20) away from the base part (10) is in the range of 1 mm to 2 mm.

Images